4.5 Article

Joint longitudinal hurdle and time-to-event models: an application related to viral load and duration of the first treatment regimen in patients with HIV initiating therapy

Journal

STATISTICS IN MEDICINE
Volume 35, Issue 20, Pages 3583-3594

Publisher

WILEY-BLACKWELL
DOI: 10.1002/sim.6948

Keywords

joint model; shared parameter model; hurdle model; detection limit; censoring

Funding

  1. National Institute for Health Research (NIHR)
  2. NIHR Methods Fellowship [MET 12-20]
  3. NIHR Doctoral Research Fellowship [DRF-2012-05-409]
  4. UK Medical Research Council (MRC) [MR/J002380/1]
  5. UK Department for International Development (DFID) under the MRC/DFID
  6. EDCTP2 programme - European Union
  7. MRC [MR/J002380/1] Funding Source: UKRI
  8. Medical Research Council [MR/J002380/1] Funding Source: researchfish
  9. National Institute for Health Research [NF-SI-0611-10168, DRF-2012-05-409, MET-12-20-101, NF-SI-0512-10159] Funding Source: researchfish

Ask authors/readers for more resources

Shared parameter joint models provide a framework under which a longitudinal response and a time to event can be modelled simultaneously. A common assumption in shared parameter joint models has been to assume that the longitudinal response is normally distributed. In this paper, we instead propose a joint model that incorporates a two-part hurdle' model for the longitudinal response, motivated in part by longitudinal response data that is subject to a detection limit. The first part of the hurdle model estimates the probability that the longitudinal response is observed above the detection limit, whilst the second part of the hurdle model estimates the mean of the response conditional on having exceeded the detection limit. The time-to-event outcome is modelled using a parametric proportional hazards model, assuming a Weibull baseline hazard. We propose a novel association structure whereby the current hazard of the event is assumed to be associated with the current combined (expected) outcome from the two parts of the hurdle model. We estimate our joint model under a Bayesian framework and provide code for fitting the model using the Bayesian software Stan. We use our model to estimate the association between HIV RNA viral load, which is subject to a lower detection limit, and the hazard of stopping or modifying treatment in patients with HIV initiating antiretroviral therapy. Copyright (c) 2016 John Wiley & Sons, Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Medicine, Research & Experimental

Treatments for Chronic Kidney Disease: A Systematic Literature Review of Randomized Controlled Trials

Juan Jose Garcia Sanchez, Juliette Thompson, David A. Scott, Rachel Evans, Naveen Rao, Elisabeth Sorstadius, Glen James, Stephen Nolan, Eric T. Wittbrodt, Alyshah Abdul Sultan, Bergur V. Stefansson, Dan Jackson, Keith R. Abrams

Summary: Contemporary data suggest that augmenting RAAS inhibitors with new drug classes has the potential to improve clinical outcomes in a broad range of patients with CKD.

ADVANCES IN THERAPY (2022)

Review Health Care Sciences & Services

How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison

Valerie Aponte Ribero, Monica Daigl, Yasmina Marti, Ksenija Gorni, Rachel Evans, David Alexander Scott, Anadi Mahajan, Keith R. Abrams, Neil Hawkins

Summary: Indirect comparisons indicate that risdiplam is superior to nusinersen in terms of improved survival and motor function in Type 1 SMA. However, concrete conclusions couldn't be drawn due to substantial differences in study populations for comparisons with onasemnogene abeparvovec in Type 1 SMA and nusinersen in Types 2/3 SMA.

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2022)

Article Medicine, General & Internal

Effect of Transcatheter Aortic Valve Implantation vs Surgical Aortic Valve Replacement on All-Cause Mortality in Patients With Aortic Stenosis A Randomized Clinical Trial

William D. Toff, David Hildick-Smith, Jan Kovac, Michael J. Mullen, Olaf Wendler, Anita Mansouri, Ines Rombach, Keith R. Abrams, Simon P. Conroy, Marcus D. Flather, Alastair M. Gray, Philip MacCarthy, Mark J. Monaghan, Bernard Prendergast, Simon Ray, Christopher P. Young, David C. Crossman, John G. F. Cleland, Mark A. de Belder, Peter F. Ludman, Stephen Jones, Cameron G. Densem, Steven Tsui, Manoj Kuduvalli, Joseph D. Mills, Adrian P. Banning, Rana Sayeed, Ragheb Hasan, Douglas G. W. Fraser, Uday Trivedi, Simon W. Davies, Alison Duncan, Nick Curzen, Sunil K. Ohri, Christopher J. Malkin, Pankaj Kaul, Douglas F. Muir, W. Andrew Owens, Neal G. Uren, Renzo Pessotto, Simon Kennon, Wael Awad, Saib S. Khogali, Maciej Matuszewski, Richard J. Edwards, Bandigowdanapalya C. Ramesh, Miles Dalby, Shahzad G. Raja, Giovanni Mariscalco, Clinton Lloyd, Ian D. Cox, Simon R. Redwood, Mark G. Gunning, Paul D. Ridley

Summary: This study aimed to determine whether TAVI was noninferior to surgery in patients at moderately increased operative risk. The results showed that among patients aged 70 years or older with severe, symptomatic aortic stenosis and moderately increased operative risk, TAVI was noninferior to surgery with respect to all-cause mortality at 1 year.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Article Medicine, General & Internal

Risk factors associated with SARS-CoV-2 infection in a multiethnic cohort of United Kingdom healthcare workers (UK-REACH): A cross-sectional analysis

Christopher Martin, Daniel F. Pan, Carl Melbourne, Lucy Teece, Avinash Aujayeb, Rebecca Baggaley, Luke L. Bryant, Sue Carr, Bindu Gregary, Amit Gupta, Anna B. Guyatt, Catherine John, I. Chris McManus, Joshua D. Nazareth, Laura Nellums, Rubina Reza, Sandra Simpson, Martin R. Tobin, Katherine J. Woolf, Stephen Zingwe, Kamlesh Khunti, Keith Abrams, Laura Gray, Manish Pareek

Summary: This study identified key sociodemographic and occupational risk factors associated with SARS-CoV-2 infection among UK HCWs, highlighting the importance of social and occupational factors in driving ethnic disparities in COVID-19 outcomes.

PLOS MEDICINE (2022)

Article Health Care Sciences & Services

Access to personal protective equipment in healthcare workers during the COVID-19 pandemic in the United Kingdom: results from a nationwide cohort study (UK-REACH)

Christopher A. Martin, Daniel Pan, Joshua Nazareth, Avinash Aujayeb, Luke Bryant, Sue Carr, Laura J. Gray, Bindu Gregary, Amit Gupta, Anna L. Guyatt, Alan Gopal, Thomas Hine, Catherine John, I. Chris McManus, Carl Melbourne, Laura B. Nellums, Rubina Reza, Sandra Simpson, Martin D. Tobin, Katherine Woolf, Stephen Zingwe, Kamlesh Khunti, Manish Pareek

Summary: During the COVID-19 pandemic in the UK, a significant number of healthcare workers did not have consistent access to appropriate personal protective equipment (PPE). Older healthcare workers and those working in intensive care units were more likely to have consistent access to PPE, while Asian healthcare workers, those in allied health professional and dental roles, and those who saw a higher number of COVID-19 patients were less likely to have consistent access to PPE.

BMC HEALTH SERVICES RESEARCH (2022)

Article Health Care Sciences & Services

Bayesian network meta-analysis methods for combining individual participant data and aggregate data from single arm trials and randomised controlled trials

Janharpreet Singh, Sandro Gsteiger, Lorna Wheaton, Richard D. Riley, Keith R. Abrams, Clare L. Gillies, Sylwia Bujkiewicz

Summary: This study develops a method for synthesizing data from single-arm trials and randomized controlled trials in network meta-analysis to estimate relative treatment effects. The study finds that incorporating single-arm trials in network meta-analysis may be useful in some situations where a treatment is not directly compared to other treatments.

BMC MEDICAL RESEARCH METHODOLOGY (2022)

Article Mathematical & Computational Biology

Use of copula to model within-study association in bivariate meta-analysis of binomial data at the aggregate level: A Bayesian approach and application to surrogate endpoint evaluation

Tasos Papanikos, John R. Thompson, Keith R. Abrams, Sylwia Bujkiewicz

Summary: Bivariate meta-analysis is a useful method for combining information from related studies and evaluating treatment efficacy. However, the standard approach may lead to biased results when modeling surrogate endpoints. This article proposes new modeling methods to improve the assessment of surrogate endpoints.

STATISTICS IN MEDICINE (2022)

Article Medicine, General & Internal

Hesitancy for receiving regular SARS-CoV-2 vaccination in UK healthcare workers: a cross-sectional analysis from the UK-REACH study

Neyme Veli, Christopher A. Martin, Katherine Woolf, Joshua Nazareth, Daniel Pan, Amani Al-Oraibi, Rebecca F. Baggaley, Luke Bryant, Laura B. Nellums, Laura J. Gray, Kamlesh Khunti, Manish Pareek

Summary: This study found that nearly a quarter of UK HCWs were hesitant about receiving a regular SARS-CoV-2 vaccination. Black HCWs, those with previous COVID-19 episodes, and those who have not received influenza vaccination were more likely to be hesitant. On the other hand, HCWs who received influenza vaccination and trusted official vaccine information were less likely to hesitate.

BMC MEDICINE (2022)

Article Public, Environmental & Occupational Health

Double-counting of populations in evidence synthesis in public health: a call for awareness and future methodological development

Humaira Hussein, Clareece R. Nevill, Anna Meffen, Keith R. Abrams, Sylwia Bujkiewicz, Alex J. Sutton, Laura J. Gray

Summary: This study investigates the issue of double-counting of individuals in evidence synthesis using real-world and observational data in public health. It highlights the challenges and proposes potential solutions, emphasizing the need for methodological development and guidelines to address this issue.

BMC PUBLIC HEALTH (2022)

Article Public, Environmental & Occupational Health

Cohort Profile: The United Kingdom Research study into Ethnicity and COVID-19 outcomes in Healthcare workers (UK-REACH)

Luke Bryant, Robert C. Free, Katherine Woolf, Carl Melbourne, Anna L. Guyatt, Catherine John, Amit Gupta, Laura J. Gray, Laura Nellums, Christopher A. Martin, I. Chris McManus, Claire Garwood, Vishant Modhawdia, Sue Carr, Louise Wain, Martin D. Tobin, Kamlesh Khunti, Ibrahim Akubakar, Manish Pareek

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2022)

Article Health Care Sciences & Services

Bridging disconnected networks of first and second lines of biologic therapies in rheumatoid arthritis with registry data: bayesian evidence synthesis with target trial emulation

Sylwia Bujkiewicz, Janharpreet Singh, Lorna Wheaton, David Jenkins, Reynaldo Martina, Kimme L. Hyrich, Keith R. Abrams

Summary: This study aims to optimize the evidence base for biologic therapies in rheumatoid arthritis using real-world data, allowing evidence on first-line therapies to inform estimates of effectiveness in second-line treatment. By emulating treatment sequences and conducting a bivariate network meta-analysis, the study provides effectiveness estimates for both first-line and second-line treatments.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2022)

Review Oncology

Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups

Chinyereugo M. M. Umemneku-Chikere, Olubukola Ayodele, Marta Soares, Sam Khan, Keith Abrams, Rhiannon Owen, Sylwia Bujkiewicz

Summary: This review examines the reporting of evidence for the treatment effects in HER2-positive advanced breast cancer (ABC) patients based on hormone receptor status. The study highlights a lack of reporting on the effectiveness of therapies based on hormone receptor subgroups in the identified randomized controlled trials (RCTs), with only a minority reporting progression-free survival. The analysis suggests that future trials in ABC should include reporting on the effects of cancer therapies in hormone receptor subgroups for all outcomes.

FRONTIERS IN ONCOLOGY (2022)

Article Economics

Cost-Effectiveness Analysis of Siltuximab for Australian Public Investment in the Rare Condition Idiopathic Multicentric Castleman Disease

Francis Shupo, Keith R. Abrams, Zanfina Ademi, Grace Wayi-Wayi, Natasa Zibelnik, Matt Kirchmann, Carolyn Rutherford, Kelly Makarounas-Kirchmann

Summary: This paper presents an Australian model for the assessment of the cost-effectiveness of siltuximab for idiopathic Multicentric Castleman Disease (iMCD) in Australia. The model was informed by literature reviews, clinical trial data, and stakeholder input, and estimated an incremental cost-effectiveness ratio of A$84,935 per quality-adjusted life-year (QALY) gained. The results suggest that siltuximab has a 72.1% probability of being cost-effective compared with placebo and best supportive care at a willingness-to-pay threshold of A$100,000 per QALY.

PHARMACOECONOMICS-OPEN (2023)

Correction Geriatrics & Gerontology

The association between frailty risk and COVID-19-associated all-mortality in hospitalised older people: a national cohort study (June, 10.1007/s41999-022-00668-8, 2022)

Laia Maynou, Rhiannon Owen, Rob Konstant-Hambling, Towhid Imam, Suzanne Arkill, Deborah Bertfield, Andrew Street, Keith R. Abrams, Simon Conroy

EUROPEAN GERIATRIC MEDICINE (2022)

Article Geriatrics & Gerontology

The association between frailty risk and COVID-19-associated all-mortality in hospitalised older people: a national cohort study

Laia Maynou, Rhiannon Owen, Rob Konstant-Hambling, Towhid Imam, Suzanne Arkill, Deborah Bertfield, Andrew Street, Keith R. Abrams, Simon Conroy

Summary: This study investigated the impact of COVID-19 and frailty risk on mortality in older people, and found that intermediate and high frailty risk were associated with increased mortality risk compared to low frailty risk. Any level of elevated frailty risk should be considered an important prognostic marker for older people hospitalized with COVID-19.

EUROPEAN GERIATRIC MEDICINE (2022)

No Data Available